OS Therapies (NYSE:OSTX) Research Coverage Started at Lake Street Capital

Lake Street Capital started coverage on shares of OS Therapies (NYSE:OSTX) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $19.00 target price on the stock.

A number of other research analysts have also recently commented on OSTX. Maxim Group raised their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. D. Boral Capital reissued a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Monday, March 31st. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.00.

OS Therapies Price Performance

Shares of OS Therapies stock opened at $1.40 on Wednesday. The company’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $2.68. OS Therapies has a 12-month low of $1.33 and a 12-month high of $7.00.

Insider Activity at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the transaction, the insider now owns 2,531,211 shares in the company, valued at $17,060,362.14. This trade represents a 0.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 13.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC purchased a new position in OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.